Synthetic Biologics
Apr 24, 2018
Notizia
FDA still not completely satisfied with Kamada’s inhaled AAT drug(Synthetic Biologics) Kamada is stuck again with a new obstacle in its way to bring the first inhaled treatment for alpha-1 antitrypsin (AAT) deficiency in the market as an alternative to currently present intravenous drugs. The company specializes in ...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
